GlassScriptPhysician profile
Allissa K Joseph
NPI 1487179818
$2,183.15
in general payments reported to CMS, 2019-2025
21 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $72.42 · 2024: $1,114 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.16 |
| Education | $155.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.43 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $321.00 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $249.48 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $240.13 | 2024 | Qelbree |
| Gilead Sciences, INC. | $142.53 | 2022 | |
| Novo Nordisk INC | $119.08 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $95.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $69.60 | 2023-2025 | |
| Astellas Pharma US INC | $62.79 | 2023-2024 | Veozah |
| Vanda Pharmaceuticals INC. | $57.29 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $49.20 | 2023-2024 | Farxiga, Airsupra |
| Boston Scientific Corporation | $40.61 | 2025 | Watchman |
| Exact Sciences Corporation | $37.49 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $33.77 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.26 | 2024-2025 | Xifaxan, Trulance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $30.83 | 2024 | Vistaseal |
| Otsuka America Pharmaceutical, INC. | $21.95 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $19.89 | 2025 | Gemtesa |
| Pfizer INC. | $19.88 | 2024 | |
| Evofem Biosciences, INC. | $13.81 | 2024 | |
| Ironshore Pharmaceuticals INC. | $13.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allissa Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.